Clinical Trials
146 trialsCollection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
National Institutes of Health Clinical Center (CC)
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
National Institutes of Health Clinical Center (CC)
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Institutes of Health Clinical Center (CC)
VERDI
Dana-Farber Cancer Institute
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
LEARN
University of Sydney
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
Clinical Application of CAIX-Targeted PET Imaging in Tumors
Peking University Cancer Hospital & Institute
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
iCaRe2
University of Nebraska
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
NORDIC-SUN
University of Aarhus
TDM for Optimized Outcome in Patients With mRCC.
University of Aarhus
ARC-20
Arcus Biosciences, Inc.
BASECAMP-1
A2 Biotherapeutics Inc.
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
DUAL-NK RCC
Beijing Biotech
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
National Institutes of Health Clinical Center (CC)
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
National Institutes of Health Clinical Center (CC)
COSTAR-002
Peking University First Hospital
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
FIT-001
Kura Oncology, Inc.
Rein3DP-M
University Hospital, Bordeaux
RCCETT
Peking University Third Hospital
NEOPAX
University of Colorado, Denver
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Kidney Cancer DNA Registry
Memorial Sloan Kettering Cancer Center
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
National Institutes of Health Clinical Center (CC)
STEALTH-001
KaliVir Immunotherapeutics
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
NEPHRAMBU
GCS Ramsay Santé pour l'Enseignement et la Recherche
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
Henry Ford Health System
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
PP-RECURK
Gødstrup Hospital
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SPARCC
Dana-Farber Cancer Institute
NAMECAR
Institut Paoli-Calmettes
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Tel-Aviv Sourasky Medical Center
MetroWilms
Centre Oscar Lambret
64Cu-GRIP B in Patients With Advanced Malignancies
University of California, San Francisco
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
68Ga-PSMA PET in the Renal Cell Carcinoma
Xijing Hospital